http://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here
 

 

 

Latest News !
 

Ausbiotech, Biotech Daily: 'Don't Cut the 45% R&D Tax Incentive'
- Sep 13, 2016

Pro Medicus: The Roll-Out Has Just Begun - Aug 22, 2016 

Protagonist Raises $117m, Lists on Nasdaq For Peptide Drugs

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

2015 - The Year In Review

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization

 

November BDI-40 Down 5%, ASX200 Up 2%
Big Caps Down 2%, NBI Up 7%

Neuren Up 51%, Actinogen 30%; Impedimed Down 25%

 

December 1, 2016
 
The Biotech Daily Top 40 Index (BDI-40) fell 4.6 percent in November on a plethora of mainly small falls, countered by a few small rises.
 
The ASX200 recovered 2.3 percent, while the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped a collective 1.6 percent, while the Nasdaq Biotechnology Index climbed 6.8 percent.
 
Resmed’s 6.0 percent rise to $11,694 million was insufficient to counter the Cochlear 7.2 percent fall to $6,817 million and CSL’s 2.5 percent, $1,141 million slip to $44,684 million.
 
Despite the November BDI-40 falls, for the year to November 30, 2016, the BDI-40 climbed 13.3 percent, compared to the ASX200 up 5.3 percent, the Big Caps falling 0.6 percent and the NBI losing 18.1 percent (see chart below).
 
Just 10 of the BDI-40 companies were up in November, with only five up by more than 10 percent, while 26 fell, with 16 down by more than 10 percent and four were unchanged.
 
Neuren was the best of November’s few, up 50.6 percent to $116 million, followed by Actinogen (30.4%), Ellex (26.6%), Factor Therapeutics (20.8%) and Living Cell (15.0%).
 
Impedimed led the falls, down 25.1 percent to $457 million, followed by Cyclopharm (22.9%), Atcor (21.1%), Dimerix (20.0%), IDT (19.0%), Medical Developments (17.0%), Prana (16.2%), Uscom (14.8%), Psivida (14.1%), Compumedics and Reva (13.8%).
 
Outside the BDI-40, Noxopharm jumped 81.8 percent from a low base to $20 million with Medlab Clinical up 46.6 percent, Genetic Technologies up 40.9 percent and Optiscan up 35.7 percent, while Innate continued upwards to $169 million, a 312.2 percent gain on its market capitalization 12 months ago.
 
On the Nasdaq, Aviragen (Biota) recovered 14.1 percent to $73 million, Sunshine Heart was flat at $6 million and Israel’s Redhill shed 5.5 percent to $188 million.
 
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Nov 30, 2016 
 
 
BDI-40 v S&P ASX200 Nov 30, 2015 to Nov 30, 2016 
 
Big Caps (Cochlear, CSL, Resmed) Nov 30, 2015 to Nov 30, 2016
 
 
 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At November 30, 2016

 

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in